Dynamic Changes in Circulating Tumour Cells Protein Expression

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

December 17, 2024

Study Completion Date

December 18, 2027

Conditions
Recurrence Free Survival
Interventions
DRUG

panitumumab (EGFR inhibitors)

Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression

Trial Locations (1)

88100

RECRUITING

Natalia Malara, Germaneto

All Listed Sponsors
lead

Matteo's Friends

OTHER